Skip to content

The modified Atkins diet for epilepsy: an RCT.

The modified Atkins diet in patients with refractory epilepsy and severe intellectual disability: a randomized controlled trial.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON21112
Enrollment
54
Registered
2013-08-06
Start date
2014-01-08
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Keywords: Refractory Epilepsy Intellectual disability Modified Atkins Diet In Dutch: Refractaire epilepsie Verstandelijke beperking Gemodificeerde Atkins dieet

Interventions

The intervention group will be treated with the MAD for at least 4 months, with a total follow-up of at least 6 months. After the 4-month trial period, the control group can be started on the MAD as w

Sponsors

Tergooiziekenhuizen
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Age > 18 years, moderate to severe ID; • Refractory epilepsy, defined as failure of two tolerated and appropriately chosen and used AED schedules; • More than two seizures per month, which are judged by the carers and the treating physician to impose a significant impact on the patients’ QOL –-justifying treatment; • Informed consent obtained by at least one legal representative;

Exclusion criteria

Exclusion criteria: • Undergone epilepsy surgery in the last 6 months, or awaiting presurgical evaluation; • Underwent implantation of a vagal nerve stimulation in the last 6 months; • Previous use of the MAD or the KD for more than 7 days in the last year prior to inclusion; • Hypercholesterolemia (total cholesterol >8), known cardiovascular disease or kidney failure, known metabolic disorders; • Severe underweight, defined as a BMI < 16.5; • Diabetes Mellitus.

Design outcomes

Primary

MeasureTime frame
The main study parameter will be the number of responders 4 months after randomization, compared between the intervention and the control group. Responder is defined by >50% reduction in seizure frequency.

Secondary

MeasureTime frame
Retention of the diet; change in daily functioning; feasibility of the MAD in this population and setting; adverse events attributable to the MAD; predictive factors of efficacy of the diet.

Contacts

Public ContactH.M. Hulshof

Physician - medical researcher Department of Neurology Tergooiziekenhuizen Postbus 10016 1201 DA Hilversum The Netherlands

hhulshof@tergooi.nl0887531753

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)